Abstract
Within the last two decades, various vectors based on human viruses have been developed as gene transfer vehicles for gene therapy applications and vaccination. However, one yet unresolved problem connected to the use of viral vectors in humans is the pre-existing immunity to most of these vectors in the vast majority of the population which can result in impaired gene transfer efficiency and increased secondary toxicity. One approach to solve this problem is the development of recombinant viruses of non-human origin as vectors for gene transfer. The major rationale for using such vectors is the avoidance of vector neutralization by pre-existing antibodies directed against the virus on which the vector is based. Use of vectors based on non-human viruses may therefore allow the use of lower initial vector doses to achieve efficient gene transfer. Side-effects caused by interactions between vectors derived from human viruses with a primed immune system or with blood components could also be reduced. Fu rthermore, these vectors might show new cell type tropisms and could therefore infect tissues and organs that are not accessible to current viral vectors. This review outlines some of the problems inherent in the human origin of current viral vectors and describes features and progress with non-human adenovirus and baculovirus-derived vectors that may provide alternatives.
Keywords: DNA-Vectors, Gene Delivery, OVINE ADENOVIRUS, BACULOVIRUS
Current Gene Therapy
Title: Advances in the Development of Non-Human Viral DNA-Vectors for Gene Delivery
Volume: 2 Issue: 2
Author(s): Peter Loser, Andreas Huser, Moritz Hillgenberg, Daniel Kumin, Gerald W. Both and Christian Hofimann
Affiliation:
Keywords: DNA-Vectors, Gene Delivery, OVINE ADENOVIRUS, BACULOVIRUS
Abstract: Within the last two decades, various vectors based on human viruses have been developed as gene transfer vehicles for gene therapy applications and vaccination. However, one yet unresolved problem connected to the use of viral vectors in humans is the pre-existing immunity to most of these vectors in the vast majority of the population which can result in impaired gene transfer efficiency and increased secondary toxicity. One approach to solve this problem is the development of recombinant viruses of non-human origin as vectors for gene transfer. The major rationale for using such vectors is the avoidance of vector neutralization by pre-existing antibodies directed against the virus on which the vector is based. Use of vectors based on non-human viruses may therefore allow the use of lower initial vector doses to achieve efficient gene transfer. Side-effects caused by interactions between vectors derived from human viruses with a primed immune system or with blood components could also be reduced. Fu rthermore, these vectors might show new cell type tropisms and could therefore infect tissues and organs that are not accessible to current viral vectors. This review outlines some of the problems inherent in the human origin of current viral vectors and describes features and progress with non-human adenovirus and baculovirus-derived vectors that may provide alternatives.
Export Options
About this article
Cite this article as:
Loser Peter, Huser Andreas, Hillgenberg Moritz, Kumin Daniel, Both W. Gerald and Hofimann Christian, Advances in the Development of Non-Human Viral DNA-Vectors for Gene Delivery, Current Gene Therapy 2002; 2 (2) . https://dx.doi.org/10.2174/1566523024605555
DOI https://dx.doi.org/10.2174/1566523024605555 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Implications of Fibroblast Growth Factors (FGFs) in Cancer: From Prognostic to Therapeutic Applications
Current Drug Targets Chromatin Modification and Senescence
Current Pharmaceutical Design Glioblastoma Targeted Gene Therapy Based on pEGFP/p53-Loaded Superparamagnetic Iron Oxide Nanoparticles
Current Gene Therapy Targeting Chk2 Kinase: Molecular Interaction Maps and Therapeutic Rationale
Current Pharmaceutical Design Local Gene Delivery for Cancer Therapy
Current Gene Therapy Inhibitors of Cyclin Dependent Kinases: Useful Targets for Cancer Treatment
Current Cancer Drug Targets The Development of MetAP-2 Inhibitors in Cancer Treatment
Current Medicinal Chemistry Myc - What We have Learned from Flies
Current Drug Targets Protein Phosphatase Inhibition: Structure Based Design. Towards New Therapeutic Agents
Current Pharmaceutical Design Targeted Theranostics Against Solid Cancer Using Metal Bond Milk Protein and Aptamers
Current Topics in Medicinal Chemistry Antiproliferative Activity of microRNA-125a and its Molecular Targets
MicroRNA Target Driven Preclinical Screening for New Antimitotic Chemotherapy Agents
Current Topics in Medicinal Chemistry New Molecular Targets of Anticancer Therapy – Current Status and Perspectives
Current Medicinal Chemistry Raloxifene: Cardiovascular Considerations
Mini-Reviews in Medicinal Chemistry Arsenic Trioxide Targets miR-125b in Glioma Cells
Current Pharmaceutical Design A Comprehensive Review on Cross-talk of Human Papilloma Virus Oncoproteins and Developmental/Self-Renewal Pathways During the Pathogenesis of Uterine Cervical Cancer
Current Molecular Medicine Rb Function in the Apoptosis and Senescence of Non-Neuronal and Neuronal Cells: Role in Oncogenesis
Current Molecular Medicine Epigenetic Therapies of Cancer
Current Cancer Therapy Reviews Cervical Cancer Diagnosis: Insights into Biochemical Biomarkers and Imaging Techniques
Combinatorial Chemistry & High Throughput Screening Ca<sup>2+</sup> Signalling in Endothelial Progenitor Cells: A Novel Means to Improve Cell-Based Therapy and Impair Tumour Vascularisation
Current Vascular Pharmacology